Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion

项目摘要 CD 34 RVO试验是一项I/II期随机、前瞻性、双盲、假对照研究， 以确定玻璃体内注射自体成人CD 34+的可行性、安全性和潜在疗效 视网膜静脉阻塞导致视力丧失的受试者的骨髓细胞。埃姆斯公司将 作为CD 34 RVO研究的数据协调中心（DCC）。与研究主席合作， 国防协调委员会主要在数据管理、统计和 运营支持，包括：研究设计中的统计领导;中期安全性和研究数据报告 数据和安全性监查委员会;与其他研究合作编写研究结果 领导和传播调查结果;设计和实施网上数据收集系统; 从研究开始到研究结束，为临床研究中心提供支持，包括研究中心监查，以确保适当的 研究的开展和良好质量的数据;提供质量保证和质量控制监督，以及 提供行政和会议支助。

PROJECT ABSTRACT The CD34RVO trial is a phase I/II randomized, prospective, double-masked, sham-controlled study with cross- over to determine the feasibility, safety and potential efficacy of intravitreal injection of autologous adult CD34+ cells from bone marrow in subjects with vision loss from retinal vein occlusion. The Emmes Corporation will serve as the Data Coordinating Center (DCC) for the CD34RVO study. In collaboration with the Study Chair, the DCC provides overall study leadership to CD34RVO mainly in areas of data management, statistical and operational support to include: statistical leadership in the study design; interim safety and study data reports to the Data and Safety Monitoring Committee; preparation of study results in collaboration with other study leadership and dissemination of findings; design and implementation of a web-based data collection system; support of the Clinical Center from study initiation to study closeout, including site monitoring to ensure proper conduct of the study and good quality data; provision of quality assurance and quality control oversight, and provision of administrative and meeting support.